Identification of Relevant Biological, Imaging, Mobility & Clinical

Status Recruiting

Clinical Trial Summary

The objective of this trial is to constitute a cohort of sarcopenic versus non-sarcopenic patients to validate the most relevant biological, imaging, mobility and clinical markers considered individually or in association for the diagnosis of sarcopenic patients.

Clinical Trial Description

This trial is part of a Research Program partly funded by a grant from the Walloon region entitled "Development of Markers of Sarcopenia Using an Integrated Approach : From Cell to Human". Consistent with the above-mentioned observation, there is not only one biological marker that perfectly matches the sarcopenia criteria but there is a range of complementary biomarkers - including but not limited to inflammation markers, products of oxidative damage, serum creatinine and urinary creatinine excretion, endocrine function, urine proteomics panel, N-terminal procollagen peptides, myostatin and agrin fragment - that will together constitute the ideal panel of markers (Fougère et al, 2015). These current biomarkers and the thresholds for correlation with clinical outcomes have to be deeply evaluated in clinical trials before being considered as good biomarkers. In addition, one research priority is to investigate and define novel biomarkers allowing an improved assessment, characterization and follow-up of elderly people with sarcopenia. Biomarkers derived from blood can indeed easily be measured in a standardized and low-cost way and are therefore very attractive. This clinical trial aims at confirming the relevance of new soluble markers and validating the most relevant biological (previously and newly identified), imaging, mobility and clinical markers for clinical research in sarcopenia. Newly identified soluble markers of sarcopenia coming from DEMAIN Research program and using secretomic approach (to be identified in secretome of human myotubes during the program research) using immunoassays on biological fluids. ;

Study Design

Related Conditions & MeSH terms

Sarcopenia

Clinical Trial Details

NCT number	NCT04569487
Study type	Interventional
Source	Artialis
Contact	Yves Henrotin, Prof
Phone	0032 4 242 77 06
Email	yves.henrotin@artialis.com
Status	Recruiting
Phase	N/A
Start date	February 11, 2021
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06287502` - Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis	N/A
Recruiting	`NCT05063279` - RELIEF - Resistance Training for Life	N/A
Completed	`NCT03644030` - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Recruiting	`NCT06143592` - Inspiratory Muscle Training on Balance, Falls and Diaphragm Thickness in the Elderly	N/A
Terminated	`NCT04350762` - Nutritional Supplementation in the Elderly With Weight Loss	N/A
Enrolling by invitation	`NCT05953116` - Managing the Nutritional Needs of Older Filipino With Due Attention to Protein Nutrition and Functional Health Study	N/A
Recruiting	`NCT04028206` - Resistance Exercise or Vibration With HMB for Sarcopenia	N/A
Enrolling by invitation	`NCT03297632` - Improving Muscle Strength, Mass and Physical Function in Older Adults	N/A
Completed	`NCT04015479` - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults	N/A
Completed	`NCT03234920` - Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	N/A
Recruiting	`NCT03998202` - Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Recruiting	`NCT04717869` - Identifying Modifiable PAtient Centered Therapeutics (IMPACT) Frailty
Completed	`NCT05497687` - Strength-building Lifestyle-integrated Intervention	N/A
Completed	`NCT03119610` - The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity	Phase 1/Phase 2
Recruiting	`NCT05711095` - The Anabolic Properties of Fortified Plant-based Protein in Older People	N/A
Recruiting	`NCT05008770` - Trial in Elderly With Musculoskeletal Problems Due to Underlying Sarcopenia - Faeces to Unravel Gut and Inflammation Translationally
Not yet recruiting	`NCT05860556` - Sustainable Eating Pattern to Limit Malnutrition in Older Adults
Recruiting	`NCT04522609` - Electrostimulation of Skeletal Muscles in Patients Listed for a Heart Transplant	N/A
Recruiting	`NCT04545268` - Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance	N/A
Recruiting	`NCT03160326` - The QUALITY Vets Project: Muscle Quality and Kidney Disease

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Identification of Relevant Biological, Imaging, Mobility and Clinical Markers for Clinical Research in Sarcopenia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms